http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
양성 및 악성 갑상샘 병변에서의 galectin-3, skp2, p27, cyclin D1 발현의 연관성
홍순억,홍민의,권귀영,김미경 대한병리학회 2008 Journal of Pathology and Translational Medicine Vol.42 No.3
Background : The overexpression of cyclin D1 and galectin-3 and the loss of p27 in thyroid cancers have recently been reported by many studies. The S-phase kinase associated protein 2 (skp2) plays an important role in the degradation of p27. We compared the correlation of the expressions of galectin-3, p27, cyclin D1 and skp2 in thyroid lesions. Methods : Sixty five cases were included in this study and immunohistochemical staining for galectin-3, skp2, p27 and cyclin D1 was performed. Results : The expression of galectin-3 increased in the order of nodular hyperplasia, follicular adenoma, follicular carcinoma and papillary carcinoma (p<0.01). The expression rate of skp2 was 0% for nodular hyperplasia, 16.7% for follicular adenoma, 33.3% for follicular carcinoma and 16.7% for papillary carcinoma. The loss of the expression of p27 was more frequently detected in papillary carcinoma ascompared with nodular hyperplasia (p<0.01). The increased expression of cyclin D1 was noted in follicular adenoma and carcinoma as compared with nodular hyperplasia (p=0.043). The expression of galectin-3 was related with the loss of a p27 expression (p<0.01), and the expression of skp2 was related with the expression of the cyclin D1 (p=0.022). Conclusions : Galectin-3 appears to be the most useful marker for making the diagnosis of thyroid lesions. The loss of a p27 expression can help differentiate nodular hyperplasia and papillary carcinoma, and the determining the expression of cyclin D1 may be helpful for the differential diagnosis of nodular hyperplasia and follicular neoplasm.
Parenteral and Oral Administration of O'nidazole ('tiberal') in Hepatic Amoebiasis
Hong, Soon-Eok,Soh, Chin-Thack,Kim, Yun-Joong INSTITUTE OF TROPICAL MEDICINE YONSEI UNIVERSITY 1978 YONSEI REPORTS ON TROPICAL MEDICINE Vol.9 No.1
"Tiberal" Roche를 12명의 아메바性 肝膿瘍 患者에게 投與하여 다음과 같은 성적을 얻었다. 그중 5명에게는 2앰플(1앰플 500mg Tibrael 含有. 사용전 7.5ml의 증유수에 용해함)을 靜脈內에 서서히 주사하고 12시간 후 같은 量을 주사하였으며 7명에게는 Tiberal錠劑(1錠中 500mg 含有)을 大人에 5錠, 小兒에 2.5錠, 單回 投與하였다. 1. 靜脈內注射群, 經口投與群 모두에서 治療되는 성적을 얻었으나 膿瘍이 많을 경우는 번복투여 또는 人爲的排出을 할 때 治療가 加速되었다. 2. Tiberal은 아메바性 肝膿瘍 患者의 高熱, 肝肥大, 腹痛, 肝壓痛등의 自他覺症勢를 短時日내에 好轉시켰다. 3. 副作用은 없었다.
Intravascular Leiomyosarcoma of the Femoral Vein - A Case Report -
박언섭,홍순억,홍민의,권귀영,이태진,유재형 대한병리학회 2008 Journal of Pathology and Translational Medicine Vol.42 No.4
Intravascular leiomyosarcomas of the femoral vein are extremely rare. Our patient was initially diagnosed with a deep vein thrombosis based on ultrasonography and venography. The thrombectomy specimen consisted of typical spindle cells with variable anaplasia arranged in a fasciculating and interlacing pattern. The final diagnosis was proved to be an intravascular leiomyosarcoma confirmed by immunohistochemical studies for smooth muscle actin, desmin, vimentin, CD34 and CD68. Intravascular leiomyosarcomas of the femoral vein are extremely rare. Our patient was initially diagnosed with a deep vein thrombosis based on ultrasonography and venography. The thrombectomy specimen consisted of typical spindle cells with variable anaplasia arranged in a fasciculating and interlacing pattern. The final diagnosis was proved to be an intravascular leiomyosarcoma confirmed by immunohistochemical studies for smooth muscle actin, desmin, vimentin, CD34 and CD68.
Fenbufen 좌제의 물리화학적 성상 및 생체이용률에 관한 연구
김종갑,홍순억 한국약제학회 1984 Journal of Pharmaceutical Investigation Vol.14 No.2
This investigation was designed to determine the release of fenbufen from suppositories and their bioavailability in rabbits. Suppositories containing fenbufen were made by the fusion method with Witepsol H-15, Wecobee and PEG 1540 base. Displacement value, weight variation, content uniformity, melting point and melting time were determined for preformulation of the fenbufen suppositories. The release rates were determined with the KP dissolution apparatus and with cellophane tube dialysis device and were increased in order of PEG 1540, Witespol H-15 and Wecobee. The bioavailabilities of fenbufen after rectal administration were also increased in order of PEG 1540, Witespol H-15 and Wecobee.
홍민의,홍순억,권기영,이태진,박언섭,차성재,도재혁,유재형 대한병리학회 2011 Journal of Pathology and Translational Medicine Vol.45 No.2
A 75-year-old man was referred to our hospital with intestinal obstruction caused by intussusception. Abdominal computed tomography (CT) revealed seven polypoid masses in the small intestine, while chest CT revealed a mass in the right lower lobe. Preoperative laboratory tests showed white blood cell (WBC) and neutrophil differential counts of 63,630/mm³ and 95%, respectively. The serum granulocyte colony-stimulating factor (G-CSF) was 114 pg/mL, which was elevated (normal range, <18.1 pg/mL). After resection of the small bowel, the WBC count decreased to 20,510/mm³. The pathology showed a poorly differentiated carcinoma with sarcomatous components confirmed by positive immunostaining of cytokeratin (AE1/AE3) and vimentin in the small intestine. Furthermore, immunohistochemistry with specific monoclonal antibodies against G-CSF was positive. A lung biopsy revealed the same histological findings as the small intestine lesion. Therefore, the patient was diagnosed as having a G-CSF producing sarcomatoid carcinoma of the lung with metastasis to the small intestine
Progressive Familial Intrahepatic Cholestasis in Korea: A Clinicopathological Study of Five Patients
강효정,홍순억,오석희,김경모,유한욱,김구환,유은실 대한병리학회 2019 Journal of Pathology and Translational Medicine Vol.53 No.4
Background: Progressive familial intrahepatic cholestasis (PFIC) is a heterogeneous group of autosomal recessive liver diseases that present as neonatal cholestasis. Little is known of this disease in Korea. Methods: The records of five patients histologically diagnosed with PFIC, one with PFIC1 and four with PFIC2, by liver biopsy or transplant were reviewed, and ATP8B1 and ABCB11 mutation status was analyzed by direct DNA sequencing. Clinicopathological characteristics were correlated with genetic mutations. Results: The first symptom in all patients was jaundice. Histologically, lobular cholestasis with bile plugs was the main finding in all patients, whereas diffuse or periportal cholestasis was identified only in patients with PFIC2. Giant cells and ballooning of hepatocytes were observed in three and three patients with PFIC2, respectively, but not in the patient with PFIC1. Immunostaining showed total loss of bile salt export pump in two patients with PFIC2 and focal loss in two. Lobular and portal based fibrosis were more advanced in PFIC2 than in PFIC1. ATP8B1 and ABCB11 mutations were identified in one PFIC1 and two PFIC2 patients, respectively. One PFIC1 and three PFIC2 patients underwent liver transplantation (LT). At age 7 months, one PFIC2 patient was diagnosed with concurrent hepatocellular carcinoma and infantile hemangioma in an explanted liver. The patient with PFIC1 developed steatohepatitis after LT. One patient showed recurrence of PFIC2 after 10 years and underwent LT. Conclusions: PFIC is not rare in patients with neonatal cholestasis of unknown origin. Proper clinicopathologic correlation and genetic testing can enable early detection and management.